Presentation
The Innovation Department invites you to meet & greet our next speaker in the series, Iván Ramos, PhD, Chief Executive Officer at POLAR NanoPharma. Member of the IRB Barcelona Alumni.
Iván will share his experience as CEO in the biotech/pharma sector and how to transition from the academia to industry.
Bridges to Industry is a meet & greet programme set up by the Innovation Dept. It provides participants the opportunity to meet key professionals in the bio sector and expand and/or consolidate a professional network. Schedule of the session:
- Presentation by the Invited Speaker about his experience as a CEO, his professional career and the transition from academia to industry
- Q&A session
- Closing remarks
Sessions are open to all IRB members (places limited). In addition, a number of places are reserved for IRB Barcelona alumni.
If you wish to participate in this session, please register before 18 September (Registration Form). Alumni should contact us at innovation@irbbarcelona.org.
Speaker: Iván Ramos, PhD, Chief Executive Officer at POLAR NanoPharma. Member of the IRB Barcelona Alumni.
Date: Thursday, 25 September 2025, 16:00-17:30.
Place: Sala 1 Torres D, Parc Científic de Barcelona (PCB).
Language: English
Audience: Open to the entire IRB Barcelona community (places limited)
Speakers
Iván Ramos, PhD, Chief Executive Officer at POLAR NanoPharma. Member of the IRB Barcelona Alumni.
Iván Ramos is an organic chemist passionate about drug delivery and discovery, with a strong belief in science as a collaborative effort to improve patients’ lives. He earned his PhD at IRB Barcelona (University of Barcelona). Since then, Iván has worked across academia and industry, developing molecularly targeted therapies, including small molecules, therapeutic peptides, ADCs, and immunotherapies, through research collaborations with biotech and pharmaceutical companies such as PharmaMar, Almirall, AstraZeneca, among others. He currently founded and leads the development of oncology nanomedicines at Polar NanoPharma, aiming to build the next generation of safer therapies for solid tumors.